Please assess the completion status of the following clinical trial:

Trial Title: Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Ewing sarcoma, rhabdomyosarcoma, osteosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, Wilms tumor or other primary renal tumor (including clear cell and rhabdoid)~* Age ≤ 21 years;~* Must be capable of treatment without general anesthesia~* Lesion size 8 mm - 3 cm~* Subjects who have lesions within 2 cm of central structures, will be eligible on a case by-case basis~* Pulmonary metastases found at relapse (does not have to be first relapse); no more than 3 lesions per hemi-thorax will be treated but other lesions in the lung may be present~* Greater than 5 weeks from doxorubicin at the time of consent, with radiation to be initiated no less than 6 weeks from doxorubicin~* Informed consent/assent~* Life expectancy \>3 months~* Pulmonary Function FEV1 ≥ 50% of predicted;~* Concurrent immunotherapy is allowed~Exclusion Criteria:~* Prior whole-lung or hemi-thorax irradiation of greater than 12 Gy received less than 6 months prior to consent (focal radiotherapy to the thorax is not an exclusion)~* Lesion larger than 3 cm in diameter~* Patients for whom surgery would be deemed appropriate rather than radiotherapy

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 Dose Level 1 [Phase I] (Type: EXPERIMENTAL): Participants with Wilms tumors or other primary renal tumors. Stereotactic Body Radiotherapy (SBRT) Dose Levels for each target lesion are three 8 Gy fractions for 24 Gy total.
- Cohort 1 Dose Level 2 [Phase I] (Type: EXPERIMENTAL): Participants with Wilms tumors or other primary renal tumors. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.
- Cohort 1 Dose Level 3 [Phase I] (Type: EXPERIMENTAL): Participants with Wilms tumors or other primary renal tumors. SBRT Dose Levels for each target lesion are three 12 Gy fractions for 36 Gy total.
- Cohort 2 Dose Level 2 [Phase I] (Type: EXPERIMENTAL): Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.
- Cohort 2 Dose Level 3 [Phase I] (Type: EXPERIMENTAL): Participants with Ewing sarcoma or rhabdomyosarcoma.SBRT Dose Levels for each target lesion are three 12 Gy fractions for 36 Gy total.
- Cohort 2 Dose Level 2 [Phase II] (Type: EXPERIMENTAL): Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.

Based on this trial design, predict the completion outcome and termination type (if applicable).